Generation Bio Co. Statistics
Total Valuation
GBIO has a market cap or net worth of $35.78 million. The enterprise value is -$28.15 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GBIO has 6.74 million shares outstanding. The number of shares has increased by 0.91% in one year.
| Current Share Class | 6.74M |
| Shares Outstanding | 6.74M |
| Shares Change (YoY) | +0.91% |
| Shares Change (QoQ) | +0.48% |
| Owned by Insiders (%) | 5.53% |
| Owned by Institutions (%) | 41.54% |
| Float | 4.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.31 |
| Forward PS | n/a |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of 0.52.
| Current Ratio | 4.44 |
| Quick Ratio | 4.28 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.81% and return on invested capital (ROIC) is -36.94%.
| Return on Equity (ROE) | -80.81% |
| Return on Assets (ROA) | -27.39% |
| Return on Invested Capital (ROIC) | -36.94% |
| Return on Capital Employed (ROCE) | -80.54% |
| Revenue Per Employee | $132,783 |
| Profits Per Employee | -$544,583 |
| Employee Count | 115 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.24% in the last 52 weeks. The beta is 1.96, so GBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | -61.24% |
| 50-Day Moving Average | 5.81 |
| 200-Day Moving Average | 4.94 |
| Relative Strength Index (RSI) | 43.29 |
| Average Volume (20 Days) | 83,562 |
Short Selling Information
The latest short interest is 41,031, so 0.61% of the outstanding shares have been sold short.
| Short Interest | 41,031 |
| Short Previous Month | 94,890 |
| Short % of Shares Out | 0.61% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 0.86 |
Income Statement
In the last 12 months, GBIO had revenue of $15.27 million and -$62.63 million in losses. Loss per share was -$9.34.
| Revenue | 15.27M |
| Gross Profit | -32.40M |
| Operating Income | -81.23M |
| Pretax Income | -62.63M |
| Net Income | -62.63M |
| EBITDA | -76.38M |
| EBIT | -81.23M |
| Loss Per Share | -$9.34 |
Full Income StatementBalance Sheet
The company has $89.62 million in cash and $26.10 million in debt, giving a net cash position of $63.53 million or $9.43 per share.
| Cash & Cash Equivalents | 89.62M |
| Total Debt | 26.10M |
| Net Cash | 63.53M |
| Net Cash Per Share | $9.43 |
| Equity (Book Value) | 50.56M |
| Book Value Per Share | 7.51 |
| Working Capital | 72.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$113.65 million and capital expenditures -$1.08 million, giving a free cash flow of -$114.74 million.
| Operating Cash Flow | -113.65M |
| Capital Expenditures | -1.08M |
| Free Cash Flow | -114.74M |
| FCF Per Share | -$17.03 |
Full Cash Flow StatementMargins
| Gross Margin | -212.17% |
| Operating Margin | -531.96% |
| Pretax Margin | -410.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.91% |
| Shareholder Yield | -0.91% |
| Earnings Yield | -177.04% |
| FCF Yield | -324.35% |
Analyst Forecast
The average price target for GBIO is $10.67, which is 100.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.67 |
| Price Target Difference | 100.94% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | -27.77% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 22, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
GBIO has an Altman Z-Score of -9.43 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.43 |
| Piotroski F-Score | 1 |
